Sanofi SA vs AT&T Inc. — how do they compare? Sanofi SA trades at $43.59 (market cap $104.30B), while AT&T Inc. trades at $24.1 (market cap $167.88B). The key difference: AT&T Inc. is the larger of the two by market cap, and Sanofi SA pays the higher dividend (5.55%). Which is the better fit depends on your goals.
| SNY | T | |
|---|---|---|
Market Cap | $104.30B | $167.88B |
Sector | Health | Media |
52-Week High | $52.34 | $29.62 |
52-Week Low | $41.33 | $20.49 |
Enterprise Value | $124.19B | $313.20B |
Dividend Yield | 5.55% | 4.53% |
Signals from Pluang's Aura AI — not financial advice
SNY trades at $43.54, up 0.14% today, with a neutral technical signal and bullish moving averages. Recent Q2 2026 earnings beat expectations, with EPS of $1.21 versus $1.10 expected, driven by strong Dupixent sales. The company raised its 2026 outlook, projecting ~10% sales growth. Financial health is solid with a P/E of 23.27 and robust operating cash flow of $10.75B in 2025, though net cash flow was minimal at $49M.
Outlook is cautiously optimistic with growth catalysts from Dupixent and new drug approvals, but risks include pipeline setbacks and competitive pressures. Analysts are mixed, with 44% buy ratings, highlighting potential upside to fair value estimates around $57, while debt levels and regulatory scrutiny pose challenges for sustained shareholder value.
AT&T (T) trades at $24.19, up 0.46% today, with a bullish technical signal from moving averages but overbought short-term RSI. The company shows strong fundamentals with a P/E of 8.09, net income margin of 16.94%, and consistent earnings beats in recent quarters. Recent news highlights its focus on fiber expansion and AI integration, while cash flow improved to $15.12B net in 2025.
Outlook is positive with a consensus price target of $27.69, offering 14.5% upside, supported by a 4.8% dividend yield. Risks include competitive pressure from SpaceX's Starlink and high debt levels. Analysts are mixed but lean bullish, with 41% buy ratings.
Trailing returns across standard periods
Latest headlines on both assets
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →AT&T Inc. is a communications holding company. The Company, through its subsidiaries and affiliates, provides local and long-distance phone service, wireless and data communications, Internet access and messaging, IP-based and satellite television, security services, telecommunications equipment, and directory advertising and publishing.
Read more on T →